PHPS1 sodium|cas:1177131-02-0|西域试剂

PHPS1 sodium,98.0%

产品编号：Bellancom-125108| CAS NO：1177131-02-0| 分子式：C₂₁H₁₄N₅NaO₆S| 分子量：487.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-125108		￥3800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PHPS1 sodium

产品介绍

PHPS1 sodium 是一种有效的选择性 Shp2 抑制剂，对 Shp2，Shp2-R362K，Shp1，PTP1B 和 PTP1B-Q 的 K_i 值分别为 0.73，5.8，10.7，5.8 和 0.47 μM。

生物活性

PHPS1 sodium is a potent and selective Shp2 inhibitor with K_is of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.

体外研究

PHPS1 (30 μM; 6 days) inhibits proliferation of human tumor cells.
PHPS1 (5-20 μM; 5-360 minutes) inhibits Erk1/2 but not Akt and Stat3 phosphorylation in a dose-dependent manner.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Human cancer cell lines MDA-MB-435, HCT-116 (colon carcinoma), HCT-15 (colon carcinoma), PC-3 (prostate carcinoma), HT-29 (colon carcinoma), NCI-H661 (lung carcinoma), and Caki-1 (kidney carcinoma)
Concentration:	30 μM
Incubation Time:	6 days
Result:	Resulted in a reduction in cell number of between 0% (Caki-1) to 74% (HT-29).

Western Blot Analysis

Cell Line:	Madin-Darby canine kidney (MDCK) cells
Concentration:	5, 10, 20 μM
Incubation Time:	5, 15, 60, 120, 360 minutes
Result:	Inhibited HGF/SF (1 unit/mL)-induced phosphorylation and thus activation of Erk1/2 over a time period of 15 min to 6 h. In contrast, transient phosphorylation of Erk1/2 after 5 min was not affected. Exhibited no effect on HGF/SF-induced activation of PI3K/Akt or Stat3.

体内研究
(In Vivo)

PHPS1 (3 mg/kg; i.p. injection; every day during the last week on the high-fat diet) renders Ldlr^-/- mice less susceptible to atherosclerosis development.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ldlr^-/- (005061) mice
Dosage:	3 mg/kg
Administration:	Intraperitoneal (i.p.) injection; every day during the last week on the high-fat diet.
Result:	Revealed a significant decrease in atherosclerotic plaque size in the aorta compared with the other two groups.

体内研究

PHPS1 (3 mg/kg; i.p. injection; every day during the last week on the high-fat diet) renders Ldlr^-/- mice less susceptible to atherosclerosis development.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ldlr^-/- (005061) mice
Dosage:	3 mg/kg
Administration:	Intraperitoneal (i.p.) injection; every day during the last week on the high-fat diet.
Result:	Revealed a significant decrease in atherosclerotic plaque size in the aorta compared with the other two groups.

体内研究

PHPS1 (3 mg/kg; i.p. injection; every day during the last week on the high-fat diet) renders Ldlr^-/- mice less susceptible to atherosclerosis development.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ldlr^-/- (005061) mice
Dosage:	3 mg/kg
Administration:	Intraperitoneal (i.p.) injection; every day during the last week on the high-fat diet.
Result:	Revealed a significant decrease in atherosclerotic plaque size in the aorta compared with the other two groups.